Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Group 1: National Medical Insurance and Commercial Health Insurance - The National Healthcare Security Administration has released the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs, of which 50 are first-class innovative drugs, achieving a success rate of 88%, an increase from 76% in 2024 [1] - The updated National Medical Insurance Drug Catalog will be implemented starting January 1, 2026, marking the eighth adjustment since the establishment of the National Healthcare Security Administration and the first introduction of a commercial health insurance innovative drug catalog [1] Group 2: Haiwang Bio - Haiwang Bio announced that its stock price had deviated significantly, with a cumulative increase of over 100% from November 26 to December 5, 2025, indicating severe abnormal trading [2] - The company reported a price-to-book ratio of 7.64, which differs from industry peers, suggesting potential risks of market overheating and irrational speculation [2] Group 3: Shengxiang Bio - Shengxiang Bio disclosed that 20.72 million shares (3.58% of total shares) owned by shareholder Chen Wenyin are subject to judicial freezing, with a provision allowing for the sale of up to 4 million shares under specific conditions [3] - The judicial freeze may exert short-term pressure on the stock price, but the set minimum price for the sale provides some stability [3] Group 4: Kang En Bei Management Changes - Kang En Bei announced the resignation of Chairman Jiang Yi and board member Jiang Qian due to work adjustments, raising concerns about potential governance structure changes [4] - The departure of key executives may lead to market apprehension, but if there are no significant changes in business strategy, growth potential remains [4]

Core Points - The China Securities Regulatory Commission (CSRC) is soliciting public opinions on the draft of the "Regulations on the Supervision and Administration of Listed Companies" [5] - The National Financial Regulatory Administration has adjusted risk factors related to insurance companies' investment in stocks and insurance businesses [2][3] Group 1: Regulatory Changes - The risk factor for stocks held by insurance companies for over three years in the CSI 300 index has been reduced from 0.3 to 0.27 [3] - The risk factor for stocks held for over two years in the Sci-Tech Innovation Board has been reduced from 0.4 to 0.36 [3] - The premium risk factor for export credit insurance and overseas investment insurance has been lowered from 0.467 to 0.42, and the reserve risk factor from 0.605 to 0.545 [3] Group 2: Company News - Sun Cable announced that its major shareholder, Yili Group, completed a share reduction plan, selling approximately 21.67 million shares, which is 3% of the total share capital [7] - The stock price of Sun Cable has increased by over 90% this year, and it has experienced a "four consecutive limit-up" in recent trading days [7] - Hai Tai Development has decided to terminate its cash acquisition of Zhixue Cloud Technology due to a lack of agreement on key transaction terms [8] - Bo Hai Chemical is planning a major asset sale and related transactions, with its stock set to be suspended from trading starting December 8 [8] - Wan Ke A has decided to forgo its redemption option on a bond with a balance of 1.1 billion yuan, citing current market conditions [10]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600572 证券简称：康恩贝 公告编号：2025-072 浙江康恩贝制药股份有限公司 关于董事长、法定代表人等离任事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）董事会于2025年12月5日收到公司董事长、 法定代表人姜毅先生递交的书面辞职报告，因工作调整原因，姜毅先生向公司董事会申请辞去董事、董 事长、董事会战略与投资决策委员会委员、董事会薪酬与考核委员会委员职务，同时不再担任公司法定 代表人。同日，公司董事会还收到蒋倩女士递交的申请辞去公司董事、董事会审计委员会委员职务的书 面报告。姜毅先生、蒋倩女士辞去公司董事等相应职务后，将不再担任本公司任何职务。 一、提前离任的基本情况 ■ 二、离任对公司的影响 根据《公司法》和《公司章程》相关规定，姜毅先生、蒋倩女士的辞职申请自送达公司董事会之日起生 效。该两名董事的离任不会导致公司董事会成员人数低于法定最低人数，不会影响公司董事会的正常 ...

Core Viewpoint - The resignation of Jiang Yi and Jiang Qian from their positions at Kang En Bei is attributed to "work adjustments," raising concerns about the company's leadership stability and governance structure [2][3][7]. Group 1: Resignation Details - Jiang Yi, the chairman and legal representative, and Jiang Qian, a board member, submitted their resignation reports, effective immediately, and will no longer hold any positions within the company [2][3]. - The board has approved the nomination of Xu Jie and Jin Junli as candidates for non-independent directors, to be voted on at the upcoming shareholder meeting on December 22 [2][4]. Group 2: Company Performance - Kang En Bei reported a revenue of 4.976 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 1.27%, while net profit attributable to shareholders reached 584 million yuan, up 12.65% [3]. - The increase in net profit outpaced revenue growth due to improved performance in core business operations and an increase in the market value of shares held in Jiahe Biological [3]. Group 3: Leadership Changes - The company has experienced frequent changes in its leadership over the past two years, with Jiang Yi's tenure as chairman lasting just over a year [5][6]. - Jiang Yi succeeded Hu Jiqiang, who had been a pivotal figure in the company for nearly 40 years, guiding its strategic direction and growth [6][7]. Group 4: Governance Structure - The governance structure of Kang En Bei has undergone significant changes since the Zhejiang Provincial Foreign Trade Group took control in 2020, leading to a transition of management from Hu Jiqiang to Jiang Yi [7].

Group 1 - The company 康恩贝 (SH 600572) held a temporary board meeting on December 5, 2025, to review proposals including the adjustment of company directors [1] - For the first half of 2025, 康恩贝's revenue composition was as follows: manufacturing (pharmaceutical industry) accounted for 86.63%, commercial sales for 12.07%, and other businesses for 1.3% [1] - The current market capitalization of 康恩贝 is 11.9 billion yuan [2]

Group 1 - Shareholder of Xidiwei plans to reduce holdings by up to 3% of total shares, amounting to 12.37 million shares [2] - Minsheng Bank successfully issued 6 billion yuan of 3-year floating rate financial bonds to optimize its liability structure [3] - Baisheng Intelligent intends to acquire 51% stake in Zhongke Shengu for 100 million yuan, with a preliminary valuation of up to 200 million yuan [4] Group 2 - Junshi Biosciences received acceptance for the new drug application of Rocaqi monoclonal antibody injection for treating moderate to severe plaque psoriasis [5] - Ganneng Co. announced the successful commissioning of its clean coal power project, achieving national performance standards [6] - Yuekang Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange [7][8] Group 3 - Qingtang City received notice of expropriation for Huaneng Mall, which will be shut down pending approval processes [9] - Meilixin's controlling shareholder plans to increase holdings by 50 million to 100 million yuan, with a maximum price of 52 yuan per share [10] - Zhenghong Technology reported a 20.43% year-on-year decline in November pig sales revenue [11][12] Group 4 - GAC Group reported a 9.72% year-on-year decline in November automobile sales, totaling 179,700 units [16] - Oupokangshi received approval for clinical trials of a new eye drop for treating presbyopia [17] - Kang En Bei announced the resignation of its chairman and legal representative due to work adjustments [18] Group 5 - Jiangxi Changyun is set to receive 15.7 million yuan in compensation for the expropriation of part of its properties [28] - Tianrun Dairy reported a 2.99% month-on-month increase in November pig sales revenue [29] - New Point Software won a 54 million yuan contract for a digital smart community construction project [31]

Core Viewpoint - The company announced the resignation of its chairman and legal representative, Jiang Yi, due to work adjustments, along with the resignation of another board member, Jiang Qian [1] Group 1 - Jiang Yi submitted a written resignation report requesting to resign from his positions as director, chairman, and member of the board's strategic and investment decision-making committee, as well as the remuneration and assessment committee [1] - Jiang Qian also submitted a written report resigning from her positions as director and member of the board's audit committee [1] - Following their resignations, both Jiang Yi and Jiang Qian will no longer hold any positions within the company [1]

根据《公司法》和《公司章程》相关规定，姜毅先生、蒋倩女士的辞职申请 自送达公司董事会之日起生效。该两名董事的离任不会导致公司董事会成员人数 低于法定最低人数，不会影响公司董事会的正常运行，亦不会对公司的日常运营 产生不利影响。 截至本公告披露日，姜毅先生、蒋倩女士均未持有本公司股票，不存在未履 行完毕的公开承诺，并已按照《公司董事、高级管理人员离职管理制度》完成了 工作交接。 证券代码：600572 证券简称：康恩贝 公告编号：2025-072 浙江康恩贝制药股份有限公司 关于董事长、法定代表人等离任事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）董事会于 2025 年 12 月 5 日收到公司董事长、法定代表人姜毅先生递交的书面辞职报告，因工作调整原因，姜毅先 生向公司董事会申请辞去董事、董事长、董事会战略与投资决策委员会委员、董事会薪酬 与考核委员会委员职务，同时不再担任公司法定代表人。同日，公司董事会还收到蒋倩女 士递交的申请辞去公司董事 ...

证券代码：600572 证券简称：康恩贝 公告编号：2025-073 浙江康恩贝制药股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 （一）股东会类型和届次 2025年第二次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 22 日 14 点 50 分 召开地点：杭州市滨江区滨康路 568 号康恩贝中心 2 楼会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 22 日 至2025 年 12 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股 ...